中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

microRNA-222在肝细胞癌组织中的表达及意义

张竹青 卢书明 王花丽 徐梦杳 李春艳 辛悦 赵俊军

引用本文:
Citation:

microRNA-222在肝细胞癌组织中的表达及意义

DOI: 10.3969/j.issn.1001-5256.2017.08.018
基金项目: 

国家自然科学基金项目(81502274); 辽宁省自然科学基金资助项目(2015020324); 大连市卫生局课题; 

详细信息
  • 中图分类号: R735.7

Expression of microRNA-222 in hepatocellular carcinoma tissue and its clinical significance

Research funding: 

 

  • 摘要: 目的检测microRNA-222(miRNA-222)在肝细胞癌(HCC)组织中的表达,并探讨其临床意义。方法收集2012年1月-2014年12月于大连市中心医院、大连医科大学附属第一医院手术切除的HCC组织103例,采用实时定量PCR方法检测HCC、近癌旁肝硬化组织及远癌旁肝组织中miRNA-222的表达水平,分析miRNA-222表达与HCC临床病理特征之间的关系。计量资料多组间比较采用单因素方差分析,进一步两两比较采用Dunnett’s T3法;两组间比较采用t检验。结果 miRNA-222在HCC、近癌旁肝硬化组织及远癌旁肝组织中的表达差异有统计学意义(F=27.167,P<0.001),其在HCC组织中的相对表达量(4.543±2.029)明显高于在近癌旁肝硬化组织(3.072±0.844)及远癌旁肝组织(1.559±0.695)中的相对表达量(P值均<0.01);近癌旁肝硬化组织中miRNA-222的相对表达量显著高于远癌旁肝组织(P<0.01)。miRNA-222的表达与HCC的大小、分化程度、门静脉瘤栓、侵袭转移均有关联(t值分别为7.256、9.90...

     

  • [1]CHEN W, ZHENG R, BAADE PD, et al.Cancer statistics in China, 2015[J].CA Cancer J Clin, 2016, 66 (2) :115-132.
    [2]BARTEL DP.MicroRNAs:genomics, biogenesis, mechanism, and function[J].Cell, 2004, 116 (2) :281-297.
    [3]FU Z, QIAN F, YANG X, et al.Circulating miR-222 in plasma and its potential diagnostic and prognostic value in gastric cancer[J].Med Oncol, 2014, 31 (9) :164.
    [4]LIU S, SUN X, WANG M, et al.A microRNA 221-and 222-mediated feedback loop maintains constitutive activation of NF-κB and STAT3 in colorectal cancer cells[J].Gastroenterology, 2014, 147 (4) :847-859.
    [5]ZHANG DQ, ZHOU CK, JIANG XW, et al.Increased expression of miR-222 is associated with poor prognosis in bladder cancer[J].World J Surg Oncol, 2014, 12:241.
    [6]XU L, MA KX, DONG B, et al.Regulatory effect of miRNAs on apoptosis, migration, and cell cycle of hepatocellular carcinoma cells[J].J Clin Hepatol, 2013, 29 (7) :554-557. (in Chinese) 许力, 马珂歆, 董兵, 等.肝细胞癌中microRNA对细胞凋亡、转移和周期的调控作用[J].临床肝胆病杂志, 2013, 29 (7) :554-557.
    [7]MIRZAEI HR, SAHEBKAR A, MOHAMMADI M, et al.Circulating microRNAs in hepatocellular carcinoma:potential diagnostic and prognostic biomarkers[J].Curr Pharm Des, 2016, 22 (34) :5257-5269.
    [8]DENG X, WU JB.Updates in the research of relationship between MicroRNAs and hepatocellular carcinoma[J].Chin J Dig Surg, 2015, 14 (5) :431-433. (in Chinese) 邓曦, 吴敬波.微RNAs与肝癌关系的研究进展[J].中华消化外科杂志, 2015, 14 (5) :431-433.
    [9]WONG QW, CHING AK, CHAN AW, et al.MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling[J].Clin Cancer Res, 2010, 16 (3) :867-875.
    [10]KARAKATSANIS A, PAPACONSTANTINOU I, GAZOULI M, et al.Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance[J].Mol Carcinog, 2013, 52 (4) :297-303.
    [11]ZHANG ZZ, LIU X, WANG DQ, et al.Hepatitis B virus and hepatocellular carcinoma at the miRNA level[J].World J Gastroenterol, 2011, 17 (28) :3353-3358.
    [12]FIORINO S, BACCHI-REQQIANI ML, VISANI M, et al.MicroRNAs as possible biomarkers for diagnosis and prognosis of hepatitis B-and C-related-hepatocellular-carcinoma[J].World J Gastroenterol, 2016, 22 (15) :3907-3936.
    [13] MURAKAMI Y, YASUDA T, SAIGO K, et al.Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues[J].Oncogene, 2006, 25 (17) :2537-2545.
    [14]QI P, CHENG SQ, WANG H, et al.Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection[J].PLo S One, 2011, 6 (12) :e28486.
    [15]ZHANG Y, YAO J, HUAN L, et al.GNAI3 inhibits tumor cell migration and invasion and is post-transcriptionally regulated by miR-222 in hepatocellular carcinoma[J].Cancer Lett, 2015, 356 (2Pt B) :978-984.
    [16]GAROFALO M, DI LEVA G, ROMANO G, et al.miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation[J].Cancer Cell, 2009, 16 (6) :498-509.
    [17]TAO XC, MA DL, WU DQ.Effect of up-regulating miR-222 in Hep G2 cells on its invasion and proliferation[J].Pract Oncol J, 2015, 29 (3) :235-238. (in Chinese) 陶宣辰, 马东来, 吴德全.上调miR-222对肝癌细胞系Hep G2增殖和侵袭能力的影响[J].实用肿瘤学杂志, 2015, 29 (3) :235-238.
    [18]JIANG F, ZHAO W, ZHOU L, et al.MiR-222 targeted PUMA to improve sensitization of UM1 cells to cisplatin[J].Int J Mol Sci, 2014, 15 (12) :22128-22141.
    [19]SHEN H, WANG D, LI L, et al.MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway[J].Gene, 2017, 596:110-118.
    [20]LIU K, LIU S, ZHANG W, et al.miR 222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma[J].Int J Oncol, 2014, 45 (4) :1537-1546.
  • 加载中
计量
  • 文章访问数:  2066
  • HTML全文浏览量:  16
  • PDF下载量:  378
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-02-28
  • 出版日期:  2017-08-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回